Genmab — Juni 2025
-
Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed/Refractory Follicular Lymphoma https://www.ajmc.com/view/epcoritamab-improves-outcomes-hrqol-in-patients-with-relapsed-refractory-follicular-lymphoma EHA 2025
-
Oversigt: Ny udgave af ØU Life Science – Genmab accelererer mod blockbusterstatus med Rina-S efter data
https://proinvestor.com/investornyt/1328695/oversigt-ny-udgave-af-ou-life-science-genmab-accelererer-mod-blockbusterstatus-med-rina-s-efter-data -
(Artiklen om Genmab kræver ikke abonnement)
-
-
Lymphoma Hub
@lymphomahub
CONGRESS | #EHA2025 | PRESENTATION
Daniel Kerr,
@TGHCares presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5
trial (N = 37). https://x.com/lymphomahub/status/1934185493723263388 -
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) https://proinvestor.com/investornyt/1329270/genmab-announces-epcoritamab-investigational-combination-therapy-demonstrates-high-response-rates-in-patients-with-relapsed-or-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-eligible-for-autologous-stem-cell-trans
-
https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html Flotte resultater på Genmab bispecific vi ser i NHL og MM. Specielt imponerede med epco i first line kombo.
-
Investigational combination of first-in-class bispecifics TALVEY
and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html -
Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL https://www.onclive.com/view/fixed-duration-epcoritamab-plus-pola-r-chp-demonstrates-durable-efficacy-in-first-line-dlbcl
-
Genmab har lovende resultater med kræftmiddel i lymfekræftform https://proinvestor.com/investornyt/1329375/genmab-har-lovende-resultater-med-kraeftmiddel-i-lymfekraeftform
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind